Skip to main content
. 2019 Feb 19;42(3):270–283. doi: 10.14348/molcells.2019.2364

Fig. 2.

Fig. 2

The lung cancer cells were compared regarding their sensitivities to chemotherapies, including cisplatin (A), adriamycin (B), gefitinib (C) and paclitaxel (D).